Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2025; 31(20): 100192
Published online May 28, 2025. doi: 10.3748/wjg.v31.i20.100192
Technical success, clinical efficacy, and safety of endoscopic minor papilla interventions for symptomatic pancreatic diseases
Xu Ren, Yong-Ping Qu, Tian Xia, Xiu-Fen Tang
Xu Ren, Tian Xia, Digestive Hospital of Heilongjiang Provincial Hospital, Heilongjiang Provincial Clinical Medical Research Center for Minimally Invasive Diagnosis and Treatment of Pancreaticobiliary Diseases, Harbin 150001, Heilongjiang Province, China
Yong-Ping Qu, Digestive Endoscopy Center of Heilongjiang Provincial Hospital, Heilongjiang Provincial Clinical Medical Research Center for Minimally Invasive Diagnosis and Treatment of Pancreaticobiliary Diseases, Harbin 150001, Heilongjiang Province, China
Xiu-Fen Tang, First Department of Gastroenterology, Digestive Hospital of Heilongjiang Provincial Hospital, Heilongjiang Provincial Clinical Medical Research Center for Minimally Invasive Diagnosis and Treatment of Pancreaticobiliary Diseases, Harbin 150001, Heilongjiang Province, China
Co-first authors: Xu Ren and Yong-Ping Qu.
Author contributions: Ren X and Qu YP contributed equally to this work and share first authorship; Ren X conceived and designed the study, performed endoscopic minor papilla intervention procedures, and revised the manuscript; Qu YP assisted with the endoscopic minor papilla intervention procedures and was in charge of data collection and curation; Xia T participated in the manuscript preparation and data validation; Tang XF was responsible for the data analyses.
Supported by Heilongjiang Provincial Natural Science Foundation Team Project, No. TD2020H002.
Institutional review board statement: This retrospective study was approved by the Ethics Committee of Heilongjiang Provincial Hospital.
Informed consent statement: Informed consent from the patients was waived due to the retrospective nature.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xu Ren, PhD, Professor, Digestive Hospital of Heilongjiang Provincial Hospital, Heilongjiang Provincial Clinical Medical Research Center for Minimally Invasive Diagnosis and Treatment of Pancreaticobiliary Diseases, No. 405 Guogeli Street, Harbin 150001, Heilongjiang Province, China. hljxhy2001@126.com
Received: August 9, 2024
Revised: March 21, 2025
Accepted: May 6, 2025
Published online: May 28, 2025
Processing time: 291 Days and 19.5 Hours
Core Tip

Core Tip: The study evaluated the technical success, clinical success, stone clearance, and safety of endoscopic minor papilla intervention (EMPI) for symptomatic pancreatic diseases. Initial and overall technical success rates for deep cannulation via the minor papilla were 74.4% and 88.4%, respectively. Immediate clinical success (pain improvement) was 79.1%, and the long-term clinical success rates at 1, 3, and 7 years were 74.7%, 55.3%, and 41.5%, respectively. Stone clearance was achieved in 69.2% of cases. Post-endoscopic retrograde cholangiopancreatography pancreatitis was a main early adverse event, developed in 11.6% of cases. EMPI is a feasible, effective, and safe modality for symptomatic pancreatic diseases.